多西紫杉醇联合卡培他滨治疗蒽环类耐药的晚期乳腺癌

目的：观察多西紫杉醇联合卡培他滨方案治疗对蒽环类耐药的晚期乳腺癌的疗效及毒副反应。方法：24例患者给予多西紫杉醇75mg/m^2静滴d1,卡培他滨1650mg/m^2.d,口服,d1-d14。21天为1周期,至少用2个周期,中位化疗周期数3个（2-4周期）。结果：总有效率41.7%,疾病控制率为83.3%,中位生存期16.5个月,主要毒副作用为骨髓抑制和脱发。结论：多西紫杉醇联合卡培他滨治疗对蒽环类耐药的晚期乳腺癌疗效好,毒副作用轻,是治疗对蒽环类耐药晚期乳腺癌较好的方案。

Docetaxel and xeloda combined chemotherapy in anthracyclines resistant advanced breast cancer

Objective ：To observe the curative effect and toxicity of docetaxel plus xeloda in advanced breast cancer patients who were drug resistance to anthracene nucleus drugs. Methods： Twenty four patients received docetaxel 75mg/m^2 on dl and xeloda 1650mg/m^2 on d1 - d4 of every 21 days, every patient was admimistered not less 2 cycles and with a median of 3 cycles（2 -4 cycles）. Results： The total responsive rate was 41.7% , clinical disease control rate was 83.3% , median survival time was 16.5 months, main side effects were marrow suppress and baldness. Conclusion ： combination chemotherapy of docetaxel and capecitabine has a good anti - tumor activity and tolerable toxicity on advanced breast cancer patients who were drug resistance to anthracene nucleus drugs.